Список литературы

1. Pancreatic Cancer Guidelines. Updated: Mar 07, 2019 [Электронный ресурс]. - URL: https://emedicine.medscape.com/article/280605-guidelines#g2 (дата обращения: 16.12.2019).

2. Андрей Дмитриевич Каприн. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность)/Андрей Дмитриевич Каприн. - МНИОИ им. П.А. Герцена МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России. - Москва, 2018. - 250 с.

3. Базин И. Место химиотерапии в лечении локализованного рака поджелудочной железы/И. Базин, И. Покатаев. - 2016. - Т. 21. - N 4 (спецвыпуск 1). - С. 20 - 25.

4. Гомболевский В. Методические рекомендации по применению критериев ответа солидных опухолей на химиотерапевтическое лечение (RECIST 1.1)/В. Гомболевский, А. Лайпан, А. Шапиев//Методические рекомендации N 46. - N 2018.

5. Кармазановский Г. Дифференциальная диагностика и определение резектабельности рака поджелудочной железы с помощью МСКТ и МРТ/Г. Кармазановский. - 2019. - Т. 24. - N 3. - С. 22 - 35.

6. Кудашкин Е. Стратегия радикального лечения опухолей периампулярной локализации, осложненных механической желтухой/Е. Кудашкин. - 2012. - Т. 241. - N 8. - С. 77 - 81.

7. Патютко Ю.И. Гепатопанкреатодуоденальная резекция - есть ли перспективы?/Ю.И. Патютко. - 2011. - N 8. - С. 41 - 46.

8. Патютко Ю.И. Проксимальная и дистальная резекция поджелудочной железы с сохранением тела/Ю.И. Патютко. - 2012. - N 2. - С. 70 - 73.

9. Патютко Ю.И. Резекция сосудов в хирургии рака поджелудочной железы/Ю.И. Патютко. - 2012. - N 3. - С. 21 - 32.

10. Патютко Ю.И. Тотальная панкреатэктомия при опухолевом поражении поджелудочной железы/Ю.И. Патютко. - 2016. - N 9. - С. 13 - 20.

11. Покатаев И. Практические рекомендации по лекарственному лечению рака поджелудочной железы/И. Покатаев, А. Трякин//Злокачественные опухоли. - 2018. - Т. 8. - N 3s2. - С. 401 - 413.

12. Покатаев И. Системная лекарственная терапия метастатического рака поджелудочной железы/И. Покатаев, С. Тюляндин. - 2016. - N 1. - С. 20 - 24.

13. Berk V. XELOX versus FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Cancer/V. Berk, N. Ozdemir, M. Ozkan, и др.//Hepatogastroenterology. - 2012.

14. Boeck S. Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer/S. Boeck, R. Wilkowski, C.J. Bruns, и др.//Oncology. - 2007. - Т. 73. - N 3 - 4. - С. 221 - 227.

15. Bruera E. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer/E. Bruera, K. Macmillan, N. Kuehn, и др.//Cancer. - 1990. - Т. 66. - N 6. - С. 1279 - 1282.

16. Burch P.A. Phase III Evaluation of Octreotide <em>versus</em> Chemotherapy with 5-Fluorouracil or 5-Fluorouracil Plus Leucovorin in Advanced Exocrine Pancreatic Cancer: A North Central Cancer Treatment Group Study/P.A. Burch, M. Block, G. Schroeder, и др.//Clinical Cancer Research. - 2000. - Т. 6. - N 9. - С. 3486.

17. Burris H.A. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial./H.A. Burris, M.J. Moore, J. Andersen, и др.//Journal of Clinical Oncology. - 1997. - Т. 15. - N 6. - С. 2403 - 2413.

18. CEREDA S. XELIRI or FOLFIRI as Salvage Therapy in Advanced Pancreatic Cancer/S. CEREDA, M. RENI, A. ROGNONE, и др.//Anticancer Research. - 2010. - Т. 30. - N 11. - С. 4785 - 4790.

19. Chung M.J. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer/M.J. Chung, H. Kang, H.G. Kim, и др.//World Journal of Gastrointestinal Oncology. - 2018. - Т. 10. - N 12. - С. 505 - 515.

20. Colucci G. Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study/G. Colucci, R. Labianca, F. Di Costanzo, и др.//Journal of Clinical Oncology. - 2010. - Т. 28. - N 10. - С. 1645 - 1651.

21. Conroy T. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer/T. Conroy, F. Desseigne, M. Ychou, и др.//New England Journal of Medicine. - 2011. - Т. 364. - N 19. - С. 1817 - 1825.

22. Dahan L. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX)./L. Dahan, J.M. Phelip, K. Le Malicot, и др.//Journal of Clinical Oncology. - 2018. - Т. 36. - N 15_suppl. - С. 4000 - 4000.

23. Daly M. Genetic/familial high-risk assessment: Breast and ovarian, version 2.2017: Featured updates to the NCCN guidelines/M. Daly, R. Pilarski, M. Berry, и др.//Journal of the National Comprehensive Cancer Network: JNCCN. - 2017. - Т. 15. - С. 9 - 20.

24. DelMaschio A. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy./A. DelMaschio, A. Vanzulli, S. Sironi, и др.//Radiology. - 1991. - Т. 178. - N 1. - С. 95 - 99.

25. Ducreux M. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and /M. Ducreux, on behalf of the ESMO Guidelines Committee, A.Sa. Cuhna, и др.//Annals of Oncology. - 2015. - Т. 26. - N suppl_5. - С. v56 - v68.

26. Farma J.M. PET/CT Fusion Scan Enhances CT Staging in Patients with Pancreatic Neoplasms/J.M. Farma, A.A. Santillan, M. Melis, и др.//Annals of Surgical Oncology. - 2008. - Т. 15. - N 9. - С. 2465 - 2471.

27. Gaag N.A. van der. Preoperative Biliary Drainage for Cancer of the Head of the Pancreas/N.A. van der Gaag, E.A.J. Rauws, C.H.J. van Eijck, и др.//New England Journal of Medicine. - 2010. - Т. 362. - N 2. - С. 129 - 137.

28. Hammel P. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial/P. Hammel, F. Huguet, J.-L. van Laethem, и др.//JAMA. - 2016. - Т. 315. - N 17. - С. 1844 - 1853.

29. Holzapfel K. Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer/K. Holzapfel, C. Reiser-Erkan, A.A. Fingerle, и др.//Abdominal Imaging. - 2011. - Т. 36. - N 2. - С. 179 - 184.

30. Huang Y. Prediabetes and the risk of cancer: a meta-analysis/Y. Huang, X. Cai, M. Qiu, и др.//Diabetologia. - 2014. - Т. 57. - N 11. - С. 2261 - 2269.

31. Hulzebos E.H.J. Preoperative Intensive Inspiratory Muscle Training to Prevent Postoperative Pulmonary Complications in High-Risk Patients Undergoing CABG SurgeryA Randomized Clinical Trial/E.H.J. Hulzebos, P.J.M. Helders, N.J. и др.//JAMA. - 2006. - Т. 296. - N 15. - С. 1851 - 1857.

32. Inal A. Gemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter study (Anatolian Society of Medical Oncology)/A. Inal, F.T. Kos, E. Algin, и др.//Neoplasma. - 2012. - Т. 59. - N 03. - С. 297-301.

33. Jeurnink S.M. Gastrojejunostomy versus stent placement in patients with malignant gastric outlet obstruction: a comparison in 95 patients/S.M. Jeurnink, E.W. Steyerberg, G. van'T Hof, и др.//Journal of Surgical Oncology. - 2007. - Т. 96. - N 5. - С. 389 - 396.

34. Khorana A.A. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update/A.A. Khorana, P.B. Mangu, J. Berlin, и др.//Journal of Clinical Oncology. - 2017. - Т. 35. - N 20. - С. 2324 - 2328.

35. Li J. Endoscopic Ultrasonography for Tumor Node Staging and Vascular Invasion in Pancreatic Cancer: A Meta-Analysis/J. Li, R. He, Y. Li, и др.//Digestive Surgery. - 2014. - Т. 31. - N 4-5. - С. 297 - 305.

36. Li K.C. Simultaneous measurement of flow in the superior mesenteric vein and artery with cine phase-contrast MR imaging: value in diagnosis of chronic mesenteric ischemia. Work in progress./K.C. Li, K.L. Hopkins, R.L. Dalman, и др.//Radiology. - 1995. - Т. 194. - N 2. - С. 327 - 330.

37. Liao W.-C. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis/W.-C. Liao, K.-L. Chien, Y.-L. Lin, и др.//The Lancet Oncology. - 2013. - Т. 14. - N 11. - С. 1095 - 1103.

38. Louvet C. Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial/C. Louvet, R. Labianca, P. Hammel, и др.//Journal of Clinical Oncology. - 2005. - Т. 23. - N 15. - С. 3509 - 3516.

39. Massucco P. Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival/P. Massucco, L. Capussotti, A. Magnino, и др.//Annals of Surgical Oncology. - 2006. - Т. 13. - N 9. - С. 1201 - 1208.

40. Megibow A.J. Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of resectability--report of the Radiology Diagnostic Oncology Group./A.J. Megibow, X.H. Zhou, H. Rotterdam, и др.//Radiology. - 1995. - Т. 195. - N 2. - С. 327 - 332.

41. Modlin I.M. Chromogranin A-Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease/I.M. Modlin, B.I. Gustafsson, S.F. Moss, и др.//Annals of Surgical Oncology. - 2010. - Т. 17. - N 9. - С. 2427 - 2443.

42. Moore M.J. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group/M.J. Moore, D. Goldstein, J. Hamm, и др.//Journal of Clinical Oncology. - 2007. - Т. 25. - N 15. - С. 1960 - 1966.

43. Motosugi U. Detection of Pancreatic Carcinoma and Liver Metastases with Gadoxetic Acid-enhanced MR Imaging: Comparison with Contrast-enhanced Multi-Detector Row CT/U. Motosugi, T. Ichikawa, H. Morisaka, и др.//Radiology. - 2011. - Т. 260. - N 2. - С. 446 - 453.

44. Nagrial A.M. Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials/A.M. Nagrial, V.T. Chin, K.M. Sjoquist, и др.//Critical Reviews in Oncology/Hematology. - 2015. - Т. 96. - N 3. - С. 483 - 497.

45. Neoptolemos J.P. A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer/J.P. Neoptolemos, D.D. Stocken, H. Friess, и др.//New England Journal of Medicine. - 2004. - Т. 350. - N 12. - С. 1200 - 1210.

46. Neoptolemos J.P. Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma: The ESPAC-3 Periampullary Cancer Randomized TrialAdjuvant Therapy and Periampullary Adenocarcinoma/J.P. Neoptolemos, M.J. Moore, T.F. Cox, и др.//JAMA. - 2012. - Т. 308. - N 2. - С. 147 - 156.

47. Novarino A. Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer/A. Novarino, M.A. Satolli, I. Chiappino, и др.//American Journal of Clinical Oncology. - 2009. - Т. 32. - N 1.

48. Oettle H. Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerA Randomized Controlled Trial/H. Oettle, S. Post, P. Neuhaus, и др.//JAMA. - 2007. - Т. 297. - N 3. - С. 267 - 277.

49. Oken M.M. Toxicity and response criteria of the Eastern Cooperative Oncology Group/M.M. Oken, R.H. Creech, D.C. Tormey, и др.//American Journal of Clinical Oncology. - 1982. - Т. 5. - N 6.

50. O'Toole D. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers/D. O'Toole, A. Grossman, D. Gross, и др.//Neuroendocrinology. - 2009. - Т. 90. - N 2. - С. 194 - 202.

51. Pandit S. Incidental liver metastasis in pancreatic adenocarcinoma/S. Pandit, H. Samant, K. Kohli, и др.//Journal of Surgical Case Reports. - 2019. - Т. 2019. - N 3.

52. Park S.J. Oral chemotherapy as second-line treatment option for gemcitabine-refractory advanced pancreatic cancer with poor performance status./S.J. Park, M.A. Lee//Journal of Clinical Oncology. - 2019. - Т. 37. - N 4_suppl. - С. 405 - 405.

53. Pelzer U. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group/U. Pelzer, I. Schwaner, J. Stieler, и др.//European Journal of Cancer. - 2011. - Т. 47. - N 11. - С. 1676 - 1681.

54. Pokataev I. Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer/I. Pokataev, A. Kudaibergenova, A. Artemyeva, и др.//Journal of Gastrointestinal Cancer. - 2019. - Т. 50. - N 3. - С. 478 - 484.

55. Raimondi S. Epidemiology of pancreatic cancer: an overview/S. Raimondi, P. Maisonneuve, A.B. Lowenfels//Nature Reviews Gastroenterology &Amp; Hepatology. - 2009. - Т. 6. - С. 699.

56. Sheridan M.B. Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: a comparative study with receiver operating characteristic analysis./M.B. Sheridan, J. Ward, J.A. Guthrie, и др.//American Journal of Roentgenology. - 1999. - Т. 173. - N 3. - С. 583 - 590.

57. Silver J.K. Cancer Prehabilitation: An Opportunity to Decrease Treatment-Related Morbidity, Increase Cancer Treatment Options, and Improve Physical and Psychological Health Outcomes/J.K. Silver, J. Baima//American Journal of Physical Medicine & Rehabilitation. - 2013. - Т. 92. - N 8.

58. Tan C.R. Pancreatic cancer cachexia: a review of mechanisms and therapeutics/C.R. Tan, P.M. Yaffee, L.H. Jamil, и др.//Frontiers in Physiology. - 2014. - Т. 5.

59. Tsimopoulou I. Psychological Prehabilitation Before Cancer Surgery: A Systematic Review/I. Tsimopoulou, S. Pasquali, R. Howard, и др.//Annals of Surgical Oncology. - 2015. - Т. 22. - N 13. - С. 4117 - 4123.

60. Unno M. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05)./M. Unno, F. Motoi, Y. Matsuyama, и др.//Journal of Clinical Oncology. - 2019. - Т. 37. - N 4_suppl. - С. 189 - 189.

61. Valle J.W. Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study/J.W. Valle, D. Palmer, R. Jackson, и др.//Journal of Clinical Oncology. - 2014. - Т. 32. - N 6. - С. 504 - 512.

62. Van Tienhoven G. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial./G. Van Tienhoven, E. Versteijne, M. Suker, и др.//Journal of Clinical Oncology. - 2018. - Т. 36. - N 18_suppl. - С. LBA4002 - LBA4002.

63. Varadhachary G.R. Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy/G.R. Varadhachary, E.P. Tamm, J.L. Abbruzzese, и др.//Annals of Surgical Oncology. - 2006. - Т. 13. - N 8. - С. 1035 - 1046.

64. Wichmann M. A prospective clinical feasibility study for multimodal "fast track" rehabilitation in elective pancreatic cancer surgery./M. Wichmann. - 2006. - Т. 85. - N 4. - С. 169 - 175.

65. Wong G.Y. Effect of Neurolytic Celiac Plexus Block on Pain Relief, Quality of Life, and Survival in Patients With Unresectable Pancreatic CancerA Randomized Controlled Trial/G.Y. Wong, D.R. Schroeder, P.E. Carns, и др.//JAMA. - 2004. - Т. 291. - N 9. - С. 1092 - 1099.

66. Wren S.M. Postoperative Pneumonia-Prevention Program for the Inpatient Surgical Ward/S.M. Wren, M. Martin, J.K. Yoon, и др.//Journal of the American College of Surgeons. - 2010. - Т. 210. - N 4. - С. 491 - 495.

67. Wyse J.M. Randomized, Double-Blind, Controlled Trial of Early Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis to Prevent Pain Progression in Patients With Newly Diagnosed, Painful, Inoperable Pancreatic Cancer/J.M. Wyse, M. Carone, S.C. Paquin, и др.//Journal of Clinical Oncology. - 2011. - Т. 29. - N 26. - С. 3541 - 3546.

68. Xiong H.Q. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer/H.Q. Xiong, G.R. Varadhachary, J.C. Blais, и др.//Cancer. - 2008. - Т. 113. - N 8. - С. 2046 - 2052.

69. Zaanan A. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study/A. Zaanan, I. Trouilloud, T. Markoutsaki, и др.//BMC cancer. - 2014. - Т. 14. - С. 441.

70. Agarwal B. Endoscopic Ultrasound-Guided Fine Needle Aspiration and Multidetector Spiral CT in the Diagnosis of Pancreatic Cancer/B. Agarwal, E. Abu-Hamda, K.L. Molke, и др.//The American Journal of Gastroenterology. - 2004. - Т. 99. - N 5. - С. 844 - 850.

71. Azar I. Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: a nation-wide study/I. Azar, G. Virk, S. Esfandiarifard, и др.//Journal of Gastrointestinal Oncology. - 2019. - Т. 10. - N 4. - С. 703 - 711.

72. Cartwright T.H. Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer/T.H. Cartwright, A. Cohn, J.A. Varkey, и др.//Journal of Clinical Oncology. - 2002. - Т. 20. - N 1. - С. 160 - 164.

73. Chin V. Chemotherapy and radiotherapy for advanced pancreatic cancer/V. Chin, A. Nagrial, K. Sjoquist, и др.//Cochrane Database of Systematic Reviews. - 2018.

74. Conroy T. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer/T. Conroy, P. Hammel, M. Hebbar, и др.//New England Journal of Medicine. - 2018. - Т. 379. - N 25. - С. 2395 - 2406.

75. Demols A. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study/A. Demols, M. Peeters, M. Polus, и др.//British Journal of Cancer. - 2006. - Т. 94. - N 4. - С. 481 - 485.

76. Fathi A.H. Extended Perioperative Antibiotic Coverage in Conjunction with Intraoperative Bile Cultures Decreases Infectious Complications after Pancreaticoduodenectomy/A.H. Fathi, T. Jackson, M. Barati, и др.//HPB Surgery. - 2016. - Т. 2016. - С. 1 - 6.

77. Gilliland T. Nutritional and Metabolic Derangements in Pancreatic Cancer and Pancreatic Resection/T. Gilliland, N. Villafane-Ferriol, K. Shah, и др.//Nutrients. - 2017. - Т. 9. - N 3. - С. 243.

78. Hameed M. Pain Management in Pancreatic Cancer/M. Hameed, H. Hameed, M. Erdek//Cancers. - 2010. - Т. 3. - N 1. - С. 43 - 60.

79. Hijazi Y. A systematic review of prehabilitation programs in abdominal cancer surgery/Y. Hijazi, U. Gondal, O. Aziz//International Journal of Surgery. - 2017. - Т. 39. - С. 156 - 162.

80. Isayama H. Gemcitabine and Oxaliplatin Combination Chemotherapy for Patients with Refractory Pancreatic Cancer/H. Isayama, Y. Nakai, K. Yamamoto, и др.//Oncology. - 2011. - Т. 80. - N 1-2. - С. 97 - 101.

81. Kang S.P. Optimal Second Line Treatment Options for Gemcitabine Refractory Advanced Pancreatic Cancer Patients. Can We Establish Standard of Care with Available Data?/S.P. Kang, M.W. Saif. - С. 8.

82. Kunzmann V. 671OConversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine-or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial/V. Kunzmann, H. Alg l, E. Goekkurt, и др.//Annals of Oncology. - 2019. - Т. 30. - N Supplement_5. - С. mdz247.

83. Maire F. Long-term Outcome of Biliary and Duodenal Stents in Palliative Treatment of Patients with Unresectable Adenocarcinoma of the Head of Pancreas/F. Maire, P. Hammel, P. Ponsot, и др.//The American Journal of Gastroenterology. - 2006. - Т. 101. - N 4. - С. 735 - 742.

84. Mita N. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure/N. Mita, T. Iwashita, S. Uemura, и др.//Journal of Clinical Medicine. - 2019. - Т. 8. - N 6. - С. 761.

85. Mukherjee S. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial/S. Mukherjee, C.N. Hurt, J. Bridgewater, и др.//The Lancet Oncology. - 2013. - Т. 14. - N 4. - С. 317 - 326.

86. Neoptolemos J.P. Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial/J.P. Neoptolemos, D.D. Stocken, C. Bassi, и др.//JAMA. - 2010. - Т. 304. - N 10. - С. 1073.

87. Neoptolemos J.P. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial/J.P. Neoptolemos, D.H. Palmer, P. Ghaneh, и др.//The Lancet. - 2017. - Т. 389. - N 10073. - С. 1011 - 1024.

88. Pishvaian M.J. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative/M.J. Pishvaian, R.J. Bender, D. Halverson, и др.//Clinical Cancer Research. - 2018. - С. 1078-0432.CCR-18-0531.

89. Pokataev I. Clinical Predictors of Second-Line Chemotherapy Benefit in Patients with Pancreatic Cancer/I. Pokataev. - 2017. - С. 6.

90. Reni M. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial/M. Reni, G. Balzano, S. Zanon, и др.//The Lancet Gastroenterology & Hepatology. - 2018. - Т. 3. - N 6. - С. 413 - 423.

91. Sangisetty S.L. Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures/S.L. Sangisetty//World Journal of Gastrointestinal Surgery. - 2012. - Т. 4. - N 4. - С. 87.

92. Taher K. Treatment of Pancreatic Adenocarcinoma with FOLFIRINOX-A Study of Efficacy and Safety in a Saudi Population/K. Taher. - 2019. - С. 5.

93. Takahara N. Pancreatic Cancer With Malignant Ascites: Clinical Features and Outcomes/N. Takahara, H. Isayama, Y. Nakai, и др.//Pancreas. - 2015. - С. 1.

94. Tempero M.A. NCCN Guidelines. Pancreatic adenocarcinoma. Version 1.2019/M.A. Tempero, C. Cha, J. Hardacre, и др. - 2018. - С. 155.

95. Tschoep-Lechner K.E. Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer/K.E. Tschoep-Lechner, V. Milani, F. Berger, и др.//International Journal of Hyperthermia. - 2013. - Т. 29. - N 1. - С. 8 - 16.

96. Viaud J. Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study/J. Viaud, C. Brac, P. Artru, и др.//Digestive and Liver Disease. - 2017. - Т. 49. - N 6. - С. 692 - 696.

97. Von Hoff D.D. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine/D.D. Von Hoff, T. Ervin, F.P. Arena, и др.//New England Journal of Medicine. - 2013. - Т. 369. - N 18. - С. 1691 - 1703.

98. Wolny-Rokicka E. Tolerance and efficacy of palliative radiotherapy for advanced pancreatic cancer: A retrospective analysis of single-institutional experiences/E. Wolny-Rokicka, K. Sutkowski, A. Grzadziel, и др.//Molecular and Clinical Oncology. - 2016. - Т. 4. - N 6. - С. 1088 - 1092.

99. Yoo C. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer/C. Yoo, J.Y. Hwang, J.-E. Kim, и др.//British Journal of Cancer. - 2009. - Т. 101. - N 10. - С. 1658 - 1663.

100. Ansari D. Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment/D. Ansari, H. Friess, M. Bauden, и др.//Oncotarget. - 2018. - Т. 9. - N 5. - С. 6644 - 6651.

101. Aung K.L. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial/K.L. Aung, S.E. Fischer, R.E. Denroche, и др.//Clinical cancer research: an official journal of the American Association for Cancer Research. - 2018. - Т. 24. - N 6. - С. 1344 - 1354.

102. Buchs N.C. Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management/N.C. Buchs, M. Chilcott, P.-A. Poletti, и др.//World journal of gastroenterology. - 2010. - Т. 16. - N 7. - С. 818 - 831.

103. Duell E.J. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4)/E.J. Duell, E. Lucenteforte, S.H. Olson, и др.//Annals of oncology: official journal of the European Society for Medical Oncology. - 2012. - Т. 23. - N 11. - С. 2964 - 2970.

104. Fogelman D. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma/D. Fogelman, E.A. Sugar, G. Oliver, и др.//Cancer chemotherapy and pharmacology. - 2015. - Т. 76. - N 3. - С. 489 - 498.

105. Gudjonsson B. Pancreatic Cancer: 80 Years of Surgery-Percentage and Repetitions/B. Gudjonsson//HPB surgery: a world journal of hepatic, pancreatic and biliary surgery. - 2016. - Т. 2016. - С. 6839687 - 6839687.

106. Hu Z.I. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations/Z.I. Hu, J. Shia, Z.K. Stadler, и др.//Clinical cancer research: an official journal of the American Association for Cancer Research. - 2018. - Т. 24. - N 6. - С. 1326 - 1336.

107. Khan M.A.A. Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward/M.A.A. Khan, S. Azim, H. Zubair, и др.//International journal of molecular sciences. - 2017. - Т. 18. - N 4. - С. 779.

108. Kinkead B. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial/B. Kinkead, P.J. Schettler, E.R. Larson, и др.//Cancer. - 2018. - Т. 124. - N 3. - С. 546 - 554.

109. Le D.T. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade/D.T. Le, J.N. Durham, K.N. Smith, и др.//Science (New York, N.Y.). - 2017. - Т. 357. - N 6349. - С. 409 - 413.

110. Makohon-Moore A. Pancreatic cancer biology and genetics from an evolutionary perspective/A. Makohon-Moore, C.A. Iacobuzio-Donahue//Nature reviews. Cancer. - 2016. - Т. 16. - N 9. - С. 553 - 565.

111. Mustian K.M. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis/K.M. Mustian, C.M. Alfano, C. Heckler, и др.//JAMA oncology. - 2017. - Т. 3. - N 7. - С. 961 - 968.

112. Neuzillet C. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts/C. Neuzillet, O. Hentic, B. Rousseau, и др.//World journal of gastroenterology. - 2012. - Т. 18. - N 33. - С. 4533 - 4541.

113. Qiu M. Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value/M. Qiu, H. Qiu, Y. Jin, и др.//Journal of Cancer. - 2016. - Т. 7. - N 6. - С. 694 - 701.

114. Rocha Lino A. da. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis/A. da Rocha Lino, C.M. , R.M. , и др.//Journal of gastrointestinal oncology. - 2015. - Т. 6. - N 5. - С. 511 - 515.

115. Rombouts S.J. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer/S.J. Rombouts, M.S. Walma, J.A. Vogel, и др.//Annals of surgical oncology. - 2016. - Т. 23. - N 13. - С. 4352 - 4360.

116. Wolpin B.M. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer/B.M. Wolpin, K. Ng, Y. Bao, и др.//Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. - 2012. - Т. 21. - N 1. - С. 82 - 91.